FINACEA (azelaic acid) by Leo Pharma is mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown. First approved in 2015.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
FINACEA (azelaic acid) is a topical foam formulation approved for rosacea treatment via an unknown mechanism that interferes with pathogenic events in the disease. It is administered topically and represents a niche dermatology product with modest market penetration.
Modest revenue base with imminent patent cliff creates urgent need for commercial optimization and brand defense strategies in a contracting product lifecycle.
mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma
Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea
A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea
Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study
Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris
Worked on FINACEA at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Working on FINACEA offers limited career acceleration due to modest scale ($2M Part D spend), imminent LOE, and zero active clinical pipeline. Roles on this product are best suited for professionals seeking stable, execution-focused work or as a stepping stone to higher-growth assets at Leo Pharma.